Overview

A 98-gene lung cancer panel that separates 63 targeted-therapy-associated genes from 36 chemotherapy-response genes provides a structured view of both driver targets and likely cytotoxic sensitivity. For laboratories and distributors, the scientific content is only half the story; the assay must also meet quality and regulatory expectations before it can be used confidently. This article outlines the benchmarks that matter for such a partitioned panel.

Analytical Validation Requirements

Any NGS panel intended for clinical use requires documented validation: established sensitivity and specificity for variant classes, verified limit of detection for low-frequency variants, and demonstrated performance on FFPE and ctDNA inputs. Reproducibility across operators and reagent lots should be shown. For a panel split into targeted and chemotherapy arms, both gene sets must be validated independently so that a result in either arm is trustworthy.

Laboratory Accreditation

In many markets, clinical NGS is performed under quality systems such as CAP/CLIA in the United States or ISO 15189 equivalents elsewhere. Accreditation requires documented standard operating procedures, proficiency testing, and traceable calibration. Distributors should verify that the supplying laboratory holds the relevant accreditation for the intended market, because the same assay can carry different status across jurisdictions.

Interpretation and Reporting Standards

Variant interpretation follows consensus frameworks that grade evidence and classify results into actionable tiers. Reports should state the assay version, boundary calls, and limitations such as low tumor content. For the chemotherapy-response portion, labs must be careful to present associations as decision-support rather than fixed predictions, since response depends on many clinical factors beyond genotype.

Documentation discipline extends to version control of the gene list and bioinformatics pipeline. When either changes, the laboratory should re-validate affected components and record the effective date, so that a result from one period remains interpretable against another. This is especially important for the partitioned design, where targeted and chemotherapy arms may be updated on different schedules. Audit readiness — the ability to reconstruct how a given report was produced — is what allows regulators, accreditation bodies, and clinicians to trust the number on the page.

FAQ

Q: What validation proves a 98-gene panel is fit for use? A: Documented sensitivity, specificity, limit of detection, and reproducibility across the targeted and chemotherapy gene sets on relevant sample types.

Q: Which accreditation should a supplier hold? A: It depends on the market; CAP/CLIA is standard in the United States, while ISO 15189 equivalents apply in many other regions.

Q: Why separate targeted and chemotherapy genes? A: The split keeps driver-target results distinct from chemotherapy-response associations, supporting clearer clinical interpretation of each.

Q: Are chemotherapy-response results definitive? A: No. They are decision-support signals influenced by many clinical factors, and should be presented with appropriate caveats.